358 related articles for article (PubMed ID: 27686867)
1. Copy-number analysis identified new prognostic marker in acute myeloid leukemia.
Nibourel O; Guihard S; Roumier C; Pottier N; Terre C; Paquet A; Peyrouze P; Geffroy S; Quentin S; Alberdi A; Abdelali RB; Renneville A; Demay C; Celli-Lebras K; Barbry P; Quesnel B; Castaigne S; Dombret H; Soulier J; Preudhomme C; Cheok MH
Leukemia; 2017 Mar; 31(3):555-564. PubMed ID: 27686867
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of acquired copy-neutral loss of heterozygosity in acute myeloid leukemia.
Gronseth CM; McElhone SE; Storer BE; Kroeger KA; Sandhu V; Fero ML; Appelbaum FR; Estey EH; Fang M
Cancer; 2015 Sep; 121(17):2900-8. PubMed ID: 26033747
[TBL] [Abstract][Full Text] [Related]
3. Chromothripsis in acute myeloid leukemia: biological features and impact on survival.
Fontana MC; Marconi G; Feenstra JDM; Fonzi E; Papayannidis C; Ghelli Luserna di Rorá A; Padella A; Solli V; Franchini E; Ottaviani E; Ferrari A; Baldazzi C; Testoni N; Iacobucci I; Soverini S; Haferlach T; Guadagnuolo V; Semerad L; Doubek M; Steurer M; Racil Z; Paolini S; Manfrini M; Cavo M; Simonetti G; Kralovics R; Martinelli G
Leukemia; 2018 Jul; 32(7):1609-1620. PubMed ID: 29472722
[TBL] [Abstract][Full Text] [Related]
4. Acquired copy number alterations in adult acute myeloid leukemia genomes.
Walter MJ; Payton JE; Ries RE; Shannon WD; Deshmukh H; Zhao Y; Baty J; Heath S; Westervelt P; Watson MA; Tomasson MH; Nagarajan R; O'Gara BP; Bloomfield CD; Mrózek K; Selzer RR; Richmond TA; Kitzman J; Geoghegan J; Eis PS; Maupin R; Fulton RS; McLellan M; Wilson RK; Mardis ER; Link DC; Graubert TA; DiPersio JF; Ley TJ
Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12950-5. PubMed ID: 19651600
[TBL] [Abstract][Full Text] [Related]
5. Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis.
Mosrati MA; Willander K; Falk IJ; Hermanson M; Höglund M; Stockelberg D; Wei Y; Lotfi K; Söderkvist P
Oncotarget; 2015 Sep; 6(28):25109-20. PubMed ID: 26298771
[TBL] [Abstract][Full Text] [Related]
6. Integrated genomic profiling, therapy response, and survival in adult acute myelogenous leukemia.
Parkin B; Ouillette P; Yildiz M; Saiya-Cork K; Shedden K; Malek SN
Clin Cancer Res; 2015 May; 21(9):2045-56. PubMed ID: 25652455
[TBL] [Abstract][Full Text] [Related]
7. Presence of copy number aberration and clinical prognostic factors in patients with acute myeloid leukemia: an analysis of effect modification.
Bănescu C; Tripon F; Trifa AP; Crauciuc AG; Bogliș A; Lazar E; Dima D; Macarie I; Duicu C; Iancu M
Pol Arch Intern Med; 2019 Dec; 129(12):898-906. PubMed ID: 31808755
[TBL] [Abstract][Full Text] [Related]
8. Copy number variations in normal karyotype acute myeloid leukaemia and their association with treatment response.
Kim KI; Kim TK; Kim IW; Ahn KS; Yoon SS; Shin WG; Oh JM
Basic Clin Pharmacol Toxicol; 2012 Nov; 111(5):317-24. PubMed ID: 22672209
[TBL] [Abstract][Full Text] [Related]
9. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors for latency period and a prognostic model for survival in patients with therapy-related acute myeloid leukemia.
Ornstein MC; Mukherjee S; Mohan S; Elson P; Tiu RV; Saunthararajah Y; Kendeigh C; Advani A; Kalaycio M; Maciejewski JP; Sekeres MA
Am J Hematol; 2014 Feb; 89(2):168-73. PubMed ID: 24123154
[TBL] [Abstract][Full Text] [Related]
11. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Vujkovic M; Attiyeh EF; Ries RE; Goodman EK; Ding Y; Kavcic M; Alonzo TA; Wang YC; Gerbing RB; Sung L; Hirsch B; Raimondi S; Gamis AS; Meshinchi S; Aplenc R
Blood; 2017 Jun; 129(23):3051-3058. PubMed ID: 28411282
[TBL] [Abstract][Full Text] [Related]
12. Genome-wide identification of FHL1 as a powerful prognostic candidate and potential therapeutic target in acute myeloid leukaemia.
Fu Y; Xu M; Cui Z; Yang Z; Zhang Z; Yin X; Huang X; Zhou M; Wang X; Chen C
EBioMedicine; 2020 Feb; 52():102664. PubMed ID: 32062360
[TBL] [Abstract][Full Text] [Related]
13. INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia.
Dzneladze I; He R; Woolley JF; Son MH; Sharobim MH; Greenberg SA; Gabra M; Langlois C; Rashid A; Hakem A; Ibrahimova N; Arruda A; Löwenberg B; Valk PJ; Minden MD; Salmena L
Leukemia; 2015 Jul; 29(7):1485-95. PubMed ID: 25736236
[TBL] [Abstract][Full Text] [Related]
14. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
15. Genomics-based Approach and Prognostic Stratification Significance of Gene Mutations in Intermediate-risk Acute Myeloid Leukemia.
Wang BH; Li YH; Yu L
Chin Med J (Engl); 2015 Sep; 128(17):2395-403. PubMed ID: 26315090
[TBL] [Abstract][Full Text] [Related]
16. Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.
Vosberg S; Herold T; Hartmann L; Neumann M; Opatz S; Metzeler KH; Schneider S; Graf A; Krebs S; Blum H; Baldus CD; Hiddemann W; Spiekermann K; Bohlander SK; Mansmann U; Greif PA
Genes Chromosomes Cancer; 2016 Jul; 55(7):553-67. PubMed ID: 27015608
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of DNMT3A genetic polymorphisms as outcome predictors in AML patients.
Yuan XQ; Zhang DY; Yan H; Yang YL; Zhu KW; Chen YH; Li X; Yin JY; Li XL; Zeng H; Chen XP
Oncotarget; 2016 Sep; 7(37):60555-60574. PubMed ID: 27528035
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
von Neuhoff C; Reinhardt D; Sander A; Zimmermann M; Bradtke J; Betts DR; Zemanova Z; Stary J; Bourquin JP; Haas OA; Dworzak MN; Creutzig U
J Clin Oncol; 2010 Jun; 28(16):2682-9. PubMed ID: 20439630
[TBL] [Abstract][Full Text] [Related]
19. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
[TBL] [Abstract][Full Text] [Related]
20. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
